JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Scope & Guideline
Advancing ocular health through innovative research.
Introduction
Aims and Scopes
- Ocular Drug Development and Delivery Systems:
The journal emphasizes novel drug delivery systems and formulations designed to enhance the efficacy and safety of ocular therapeutics. This includes research on nanotechnology, polymeric micelles, and sustained-release systems. - Pharmacological Therapies for Ocular Diseases:
A core focus is on pharmacological treatments for conditions such as glaucoma, dry eye disease, and retinal disorders. This involves both systemic and topical therapies, as well as the evaluation of new pharmacological agents. - Mechanisms of Disease and Pathophysiology:
Research articles often explore the underlying mechanisms of ocular diseases, including neurodegeneration, inflammation, and fibrosis. Understanding these mechanisms is crucial for developing targeted therapies. - Clinical Trials and Efficacy Studies:
The journal publishes findings from clinical trials that assess the safety and efficacy of new treatments in human subjects, providing valuable insights into real-world applications of ocular therapeutics. - Innovative Therapeutic Modalities:
The journal includes studies on gene therapy, stem cell therapy, and other cutting-edge approaches aimed at regenerating ocular tissues and restoring vision.
Trending and Emerging
- Nanotechnology and Advanced Drug Delivery:
There is a growing trend towards exploring nanotechnology and advanced drug delivery mechanisms, with studies focusing on how these innovations can improve therapeutic outcomes in ocular diseases. - Biologics and Targeted Therapies:
Research on biologics, including monoclonal antibodies and gene therapies, is increasing. These therapies offer targeted approaches to treat complex ocular conditions, such as age-related macular degeneration and diabetic retinopathy. - Regenerative Medicine:
An emerging focus on regenerative medicine techniques, including stem cell therapy and tissue engineering, is evident. This reflects a broader interest in restoring function and repairing damaged ocular tissues. - Personalized Medicine Approaches:
The journal is increasingly publishing studies that emphasize personalized medicine, tailoring treatments based on individual patient characteristics and disease profiles. - Ocular Safety and Toxicology Studies:
There is a notable increase in research dedicated to evaluating the safety and toxicological profiles of new ocular therapies, addressing concerns about long-term effects and patient safety.
Declining or Waning
- Traditional Pharmacological Agents:
There is a noticeable decrease in studies focusing solely on traditional pharmacological agents, such as older classes of eye drops and systemic medications, as the field shifts towards more innovative therapies. - Invasive Surgical Techniques:
Research on invasive surgical techniques for treating ocular diseases is diminishing in frequency. The trend is moving towards less invasive options and pharmacological alternatives. - General Reviews without Novel Insights:
The prevalence of general review articles that do not provide novel insights or data is declining, as the journal increasingly prioritizes original research that contributes new knowledge to the field.
Similar Journals
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Transforming Knowledge into Therapeutic SolutionsThe JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Exploring the forefront of cardiovascular therapies and research.JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, published by LIPPINCOTT WILLIAMS & WILKINS, is a leading peer-reviewed journal dedicated to the exploration and advancement of pharmacological therapies related to cardiovascular diseases. With its ISSN 0160-2446 and E-ISSN 1533-4023, this esteemed journal has been at the forefront of cardiovascular research since its inception in 1979, continuously offering insights until 2024. It holds a commendable position in the 2023 category quartiles, classified as Q2 in both Cardiology and Cardiovascular Medicine, as well as Medicine (miscellaneous) and Pharmacology, showcasing its significance within these fields. The journal presents a unique platform for researchers, health professionals, and students to disseminate their findings, fostering an environment of knowledge growth and collaboration in cardiovascular pharmacology. Readers can expect to find high-quality articles that contribute to the body of knowledge in cardiovascular therapies, ensuring they remain informed of the latest advancements and clinical practices. Discover more about this influential publication and its commitment to enhancing cardiovascular health.
Augenheilkunde Up2date
Unveiling the Latest in Eye Health Developments.Augenheilkunde Up2date is a pivotal journal in the field of ophthalmology, published by GEORG THIEME VERLAG KG, a renowned publisher known for its commitment to advancing medical knowledge. With its ISSN 1616-9719 and E-ISSN 1616-9735, this journal serves as a vital resource for researchers, professionals, and students interested in the latest developments and nuanced discussions in eye health. Although not available as open access, its curated content offers significant insights into contemporary research, clinical practices, and emerging trends in ophthalmology, thus promoting the continuous professional development of its readers. There is an emphasis on providing comprehensive reviews that encapsulate the pertinent advancements in the field, making it an essential publication for those aiming to enhance their expertise in eye care and vision science.
JOURNAL FRANCAIS D OPHTALMOLOGIE
Connecting professionals to the latest in vision care advancements.JOURNAL FRANCAIS D OPHTALMOLOGIE, published by MASSON EDITEUR, is a prominent peer-reviewed journal that serves as a vital resource in the field of ophthalmology. Launched in 1978, this esteemed publication continues to make significant contributions to the advancement of ocular health and vision science, with its scope encompassing clinical practices, innovative research, and the latest technological advancements in ophthalmic care. Based in France, the journal is recognized in the 2023 category quartiles with a Q3 ranking in ophthalmology, reflecting its dedication to quality scholarship within a competitive landscape, as evidenced by its positioning in the 30th percentile of the Scopus rankings. While it operates without Open Access, the journal remains crucial for professionals, researchers, and students alike, providing a platform for sharing knowledge and fostering collaborations in the global ophthalmological community.
Therapeutic Advances in Ophthalmology
Shaping the future of ophthalmology with impactful research.Therapeutic Advances in Ophthalmology is a leading open-access journal published by SAGE Publications Ltd, dedicated to advancing the understanding and treatment of ocular diseases. Since its inception in 2018, this journal has swiftly gained prominence within the ophthalmology community, proudly holding a Q1 designation in the 2023 category quartiles and ranking 34 out of 137 in the Scopus Medicine_Ophthalmology category, placing it in the top 75th percentile. By providing a platform for innovative research, clinical advancements, and educational resources, Therapeutic Advances in Ophthalmology serves as an essential resource for researchers, healthcare professionals, and students in the field. With a commitment to disseminating high-quality research accessible to all, this journal plays a critical role in shaping the future of ophthalmic care and treatment, enabling professionals to stay abreast of the latest developments and best practices in the discipline.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
Transforming therapeutic research into real-world applications.CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL is a pivotal open-access journal published by Elsevier Science Inc., dedicated to the advancing field of clinical and experimental pharmacology. Established in 1959, this esteemed journal is committed to providing a platform for the dissemination of innovative research findings that span the entire spectrum of therapeutic sciences. With an impact factor that reflects its focus on enhancing medical knowledge and practice, CURRENT THERAPEUTIC RESEARCH serves a diverse audience of researchers, healthcare professionals, and students, striving to bridge the gap between laboratory research and clinical application. The journal has achieved a Q3 ranking in both the pharmacology and medical pharmacology categories, signifying its contribution to the field. With its open-access model initiated in 2006, it underscores the importance of research accessibility, ensuring that valuable insights reach a global audience. As the journal continues to evolve, it remains an essential resource for those devoted to improving therapeutic interventions and advancing healthcare outcomes through rigorous scientific inquiry.
FUNDAMENTAL & CLINICAL PHARMACOLOGY
Advancing pharmacological knowledge for better health outcomes.FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
Advancing the Frontiers of Vision ScienceGRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, published by Springer, has established itself as a premier journal in the field of ophthalmology since its inception in 1870. With an ISSN of 0721-832X and an E-ISSN of 1435-702X, this esteemed journal enjoys a notable impact in the research community, ranking Q1 in Ophthalmology and Q1 in Sensory Systems, as per the latest 2023 journal category quartiles. GRAEFES Archive is dedicated to advancing our understanding of ocular health through both clinical and experimental studies, making it an essential resource for researchers, practitioners, and students alike. Its comprehensive scope covers various aspects of ophthalmic science, reflecting its long-standing commitment to quality and excellence. Although it currently operates on a subscription basis, the journal's significant Scopus rankings—24th out of 137 in Ophthalmology—underscore its relevance and influence within the scientific community. Situated in Germany, with its address in the United States, this international journal continues to shape the discourse on vision science and therapeutic innovation.
Ocular Surface
Advancing the Frontiers of Ocular ResearchOcular Surface, published by Elsevier, stands at the forefront of ophthalmology research, with a notable Impact Factor reflecting its significant contribution to the field. As a vibrant platform for disseminating cutting-edge findings, this journal has achieved Q1 ranking in the Ophthalmology category as of 2023, placing it amongst the top-tier journals globally, specifically ranking 4th out of 137 in Scopus with an impressive 97th percentile. Spanning across the years from 2003 to 2024, Ocular Surface focuses on advancing knowledge in areas such as ocular pathology, therapy, and surgical interventions. While the journal is not open access, it provides invaluable insights and empirical data essential for researchers, professionals, and students dedicated to improving ocular health. With an address rooted in Amsterdam, Netherlands, this esteemed journal continues to enrich the global conversation in ophthalmology.
Drug Discoveries and Therapeutics
Shaping the landscape of modern medicine.Drug Discoveries and Therapeutics is a highly regarded journal devoted to the advancement of knowledge in the field of medicine and pharmacology. Published by the International Research & Cooperation Association for Biological & Socio-Sciences Advancement in Tokyo, Japan, this journal serves as a vital resource for researchers, practitioners, and students interested in the latest developments in drug discovery and therapeutic strategies. With a Scopus ranking of #192 out of 826 in the General Medicine category, and positioning itself in the 76th percentile, it demonstrates a significant impact within the scientific community. The journal publishes original research articles, reviews, and innovative studies that address the complexities of drug development, therapeutic efficacy, and clinical applications. Researchers and clinicians can access valuable insights to enhance their practices and inform further studies as it continues to disseminate crucial findings essential for the advancement of medical science.